JP2012505171A - 皮膚または膣粘膜へ適用するための徐放性エマルジョン - Google Patents
皮膚または膣粘膜へ適用するための徐放性エマルジョン Download PDFInfo
- Publication number
- JP2012505171A JP2012505171A JP2011530445A JP2011530445A JP2012505171A JP 2012505171 A JP2012505171 A JP 2012505171A JP 2011530445 A JP2011530445 A JP 2011530445A JP 2011530445 A JP2011530445 A JP 2011530445A JP 2012505171 A JP2012505171 A JP 2012505171A
- Authority
- JP
- Japan
- Prior art keywords
- emulsion according
- weight
- amount
- water
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 53
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 210000004877 mucosa Anatomy 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 14
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 52
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 48
- 239000012071 phase Substances 0.000 claims description 44
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 16
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 14
- 239000007764 o/w emulsion Substances 0.000 claims description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 10
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 10
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical group ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 7
- 229960003749 ciclopirox Drugs 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 239000008385 outer phase Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229920003086 cellulose ether Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 230000003232 mucoadhesive effect Effects 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- 229920013820 alkyl cellulose Polymers 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims 2
- 208000032159 Vaginal inflammation Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract description 2
- 230000005012 migration Effects 0.000 abstract description 2
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 239000013078 crystal Substances 0.000 description 14
- 238000007431 microscopic evaluation Methods 0.000 description 14
- 239000008213 purified water Substances 0.000 description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 235000019483 Peanut oil Nutrition 0.000 description 9
- 229920000148 Polycarbophil calcium Polymers 0.000 description 9
- 239000000312 peanut oil Substances 0.000 description 9
- 229950005134 polycarbophil Drugs 0.000 description 9
- 239000008309 hydrophilic cream Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- 229960002446 octanoic acid Drugs 0.000 description 5
- 229920003091 Methocel™ Polymers 0.000 description 4
- -1 alkyl methacrylates Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920001187 thermosetting polymer Polymers 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008308 lipophilic cream Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940119519 peg-32 stearate Drugs 0.000 description 2
- 229940119517 peg-6 stearate Drugs 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000021715 photosynthesis, light harvesting Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08166058.1 | 2008-10-08 | ||
| EP08166058A EP2174650A1 (en) | 2008-10-08 | 2008-10-08 | Modified release emulsions for application to skin or vaginal mucosa |
| PCT/EP2009/062190 WO2010040632A1 (en) | 2008-10-08 | 2009-09-21 | Modified release emulsions for application to skin or vaginal mucosa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505171A true JP2012505171A (ja) | 2012-03-01 |
| JP2012505171A5 JP2012505171A5 (https=) | 2012-05-17 |
Family
ID=40340663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530445A Withdrawn JP2012505171A (ja) | 2008-10-08 | 2009-09-21 | 皮膚または膣粘膜へ適用するための徐放性エマルジョン |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110195944A1 (https=) |
| EP (2) | EP2174650A1 (https=) |
| JP (1) | JP2012505171A (https=) |
| KR (1) | KR20110067115A (https=) |
| CN (1) | CN102170862A (https=) |
| AR (1) | AR073801A1 (https=) |
| AU (1) | AU2009301275A1 (https=) |
| BR (1) | BRPI0920565A2 (https=) |
| CA (1) | CA2737255A1 (https=) |
| CL (1) | CL2011000767A1 (https=) |
| CO (1) | CO6361898A2 (https=) |
| EA (1) | EA201170555A1 (https=) |
| IL (1) | IL211681A0 (https=) |
| MA (1) | MA32687B1 (https=) |
| MX (1) | MX2011003696A (https=) |
| NZ (1) | NZ591919A (https=) |
| PE (1) | PE20110449A1 (https=) |
| WO (1) | WO2010040632A1 (https=) |
| ZA (1) | ZA201101818B (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019532109A (ja) * | 2016-10-13 | 2019-11-07 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 膣送達のための凍結乾燥医薬組成物 |
| JP2020524690A (ja) * | 2017-06-22 | 2020-08-20 | ヴィラマル リミテッド | 薬物送達のための組成物およびその使用方法 |
| US12016953B2 (en) | 2018-11-30 | 2024-06-25 | Viramal Limited | Method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent |
| US12594237B2 (en) | 2018-10-26 | 2026-04-07 | Viramal Limited | Mucoadhesive gel composition |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10286056B2 (en) * | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| US9056137B2 (en) | 2011-04-01 | 2015-06-16 | University Of Florida Research Foundation, Incorporated | Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics |
| DE102011076869A1 (de) * | 2011-06-01 | 2012-12-06 | Beiersdorf Ag | Emulsionszubereitungen mit verbesserten rheologischen Eigenschaften |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CN110075310A (zh) | 2011-12-20 | 2019-08-02 | 维奥姆治疗有限公司 | 用于治疗真菌感染的局部油组合物 |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014167554A2 (en) * | 2013-04-12 | 2014-10-16 | Vyome Biosciences Pvt. Ltd. | Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections |
| CA2942345C (en) * | 2014-03-12 | 2020-12-01 | Warner Chilcott Company, Llc | Low-dose estradiol cream |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2019213473A1 (en) | 2018-05-04 | 2019-11-07 | The Procter & Gamble Company | Compositions and methods for treating vaginal dryness |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE414511T1 (de) * | 2000-12-05 | 2008-12-15 | Los Angeles Childrens Hospital | Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung |
| US20030228340A1 (en) * | 2002-04-04 | 2003-12-11 | Gans Eugene H. | Methods for treating rosacea with pyridones |
| US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
| US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
| US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
| CA2611577A1 (en) * | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
| US20070071705A1 (en) * | 2005-09-29 | 2007-03-29 | De Oliveira Monica A M | Topical anti-microbial compositions |
| US20080075745A1 (en) * | 2006-09-21 | 2008-03-27 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof |
-
2008
- 2008-10-08 EP EP08166058A patent/EP2174650A1/en not_active Withdrawn
-
2009
- 2009-09-21 US US12/998,331 patent/US20110195944A1/en not_active Abandoned
- 2009-09-21 AU AU2009301275A patent/AU2009301275A1/en not_active Abandoned
- 2009-09-21 JP JP2011530445A patent/JP2012505171A/ja not_active Withdrawn
- 2009-09-21 BR BRPI0920565A patent/BRPI0920565A2/pt not_active IP Right Cessation
- 2009-09-21 KR KR1020117007601A patent/KR20110067115A/ko not_active Withdrawn
- 2009-09-21 NZ NZ591919A patent/NZ591919A/xx not_active IP Right Cessation
- 2009-09-21 EP EP09818802A patent/EP2331065A1/en not_active Withdrawn
- 2009-09-21 PE PE2011000670A patent/PE20110449A1/es not_active Application Discontinuation
- 2009-09-21 CN CN2009801391796A patent/CN102170862A/zh active Pending
- 2009-09-21 MX MX2011003696A patent/MX2011003696A/es unknown
- 2009-09-21 EA EA201170555A patent/EA201170555A1/ru unknown
- 2009-09-21 CA CA2737255A patent/CA2737255A1/en not_active Abandoned
- 2009-09-21 WO PCT/EP2009/062190 patent/WO2010040632A1/en not_active Ceased
- 2009-10-08 AR ARP090103886A patent/AR073801A1/es unknown
-
2011
- 2011-03-09 ZA ZA2011/01818A patent/ZA201101818B/en unknown
- 2011-03-10 IL IL211681A patent/IL211681A0/en unknown
- 2011-04-01 MA MA33736A patent/MA32687B1/fr unknown
- 2011-04-06 CL CL2011000767A patent/CL2011000767A1/es unknown
- 2011-04-07 CO CO11043013A patent/CO6361898A2/es not_active Application Discontinuation
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019532109A (ja) * | 2016-10-13 | 2019-11-07 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 膣送達のための凍結乾燥医薬組成物 |
| JP7219712B2 (ja) | 2016-10-13 | 2023-02-08 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 膣送達のための凍結乾燥医薬組成物 |
| JP2020524690A (ja) * | 2017-06-22 | 2020-08-20 | ヴィラマル リミテッド | 薬物送達のための組成物およびその使用方法 |
| JP2023090986A (ja) * | 2017-06-22 | 2023-06-29 | ヴィラマル リミテッド | 薬物送達のための組成物およびその使用方法 |
| JP7345398B2 (ja) | 2017-06-22 | 2023-09-15 | ヴィラマル リミテッド | 薬物送達のための組成物およびその使用方法 |
| JP7848160B2 (ja) | 2017-06-22 | 2026-04-20 | ヴィラマル リミテッド | 薬物送達のための組成物およびその使用方法 |
| US12594237B2 (en) | 2018-10-26 | 2026-04-07 | Viramal Limited | Mucoadhesive gel composition |
| US12016953B2 (en) | 2018-11-30 | 2024-06-25 | Viramal Limited | Method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2331065A1 (en) | 2011-06-15 |
| PE20110449A1 (es) | 2011-07-07 |
| AR073801A1 (es) | 2010-12-01 |
| MX2011003696A (es) | 2011-06-20 |
| US20110195944A1 (en) | 2011-08-11 |
| CA2737255A1 (en) | 2010-04-15 |
| AU2009301275A2 (en) | 2011-04-28 |
| CN102170862A (zh) | 2011-08-31 |
| NZ591919A (en) | 2012-09-28 |
| CL2011000767A1 (es) | 2011-06-17 |
| ZA201101818B (en) | 2012-05-30 |
| WO2010040632A1 (en) | 2010-04-15 |
| BRPI0920565A2 (pt) | 2015-12-29 |
| MA32687B1 (fr) | 2011-10-02 |
| IL211681A0 (en) | 2011-06-30 |
| KR20110067115A (ko) | 2011-06-21 |
| EA201170555A1 (ru) | 2011-12-30 |
| AU2009301275A1 (en) | 2010-04-15 |
| EP2174650A1 (en) | 2010-04-14 |
| CO6361898A2 (es) | 2012-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505171A (ja) | 皮膚または膣粘膜へ適用するための徐放性エマルジョン | |
| Lala et al. | Nanoemulsion-based gel formulations of COX-2 inhibitors for enhanced efficacy in inflammatory conditions | |
| US10016442B2 (en) | Estrogen compositions for vaginal administration | |
| US6495160B2 (en) | Biphasic multicomponent pharmaceutical dosage forms containing substances able to modify the partitioning of drugs | |
| Chang et al. | Low viscosity monoglyceride-based drug delivery systems transforming into a highly viscous cubic phase | |
| JP7250689B2 (ja) | 活性化合物のための局所送達系 | |
| Kansagra et al. | Microemulsion-based antifungal gel of luliconazole for dermatophyte infections: formulation, characterization and efficacy studies | |
| US12447146B2 (en) | Topical composition comprising tacrolimus | |
| JP7384885B2 (ja) | Ｃｏｘ阻害薬を含有する経皮製剤 | |
| JP2022501314A (ja) | 局所用組成物 | |
| JP4195178B2 (ja) | 消炎鎮痛外用剤 | |
| Kracht et al. | Antifungal efficacy of liquid poloxamer 407-based emulsions loaded with sertaconazole nitrate | |
| US20170319534A1 (en) | Eutectic anesthetic topical compositions | |
| EP2910254B1 (en) | Base and external preparation for skin | |
| KR20190109511A (ko) | 국소 조성물 | |
| US12059412B2 (en) | Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof | |
| JP5662495B2 (ja) | 可溶化剤形の医薬組成物 | |
| CN111867574A (zh) | 含有双氯芬酸的乳化凝胶组合物 | |
| RU2777644C2 (ru) | Системы доставки для местного нанесения для активных веществ | |
| JP4965884B2 (ja) | 吉草酸酢酸プレドニゾロンを含有するｏ／ｗ型乳化製剤 | |
| FI56486C (fi) | Foerfarande foer framstaellning av en karbamid innehaollande farmaceutisk komposition till anvaendning foer utvaertes bruk pao maenniskohud | |
| IL318958B2 (en) | Topical administration of antifungal agents to treat fungal infections | |
| Javaid et al. | EVALUATION OF IN VITRO RELEASE OF DICLOFENAC SODIUM FORMULATED GELS THROUGH DIFFUSION CELL | |
| WO2005063207A1 (ja) | 外用非水系ゲル製剤 | |
| JP2000143439A (ja) | 乳化組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120326 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120326 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130514 |